Shares of Anthem Biosciences might be listed on the bourses as we speak. After a profitable IPO, the corporate has mounted the problem value at ₹570. In keeping with the market buzz, the inventory is prone to listing with a acquire of 20-25 per cent.
The preliminary public providing (IPO) of Bengaluru-based Anthem Biosciences Ltd (ABL) was subscribed 63.86 instances, due to sturdy assist from certified institutional patrons (QIBs).
The ₹3,395-crore IPO was fully an offer-for-sale (OFS) by promoters Ganesh Sambasivam and Ok Ravindra Chandrappa; investor shareholders Viridity Tone LLP and Portsmouth Applied sciences LLC; and different shareholders resembling Malay J Barua, Rupesh N Kinekar, Satish Sharma, Prakash Kariabettan and Ok Ramakrishnan.
As in opposition to a suggestion for 4.40 crore shares, the IPO acquired bids for 281.44 crore shares.
Whereas the QIB portion was subscribed 182.65 instances, the quota reserved for retail traders and HNIs acquired bids for five.64 instances and 42.35 instances, respectively. The portion reserved for workers (1.68 lakh shares) was subscribed 6.59 instances.
ABL is an innovation-driven and technology-focused CRDMO with fully-integrated operations in Bengaluru, spanning throughout drug discovery, improvement and manufacturing.
Anchor traders
ABL raised ₹1,016 crore from anchor traders forward of its preliminary share-sale opening for public subscription.
Among the traders who participated within the anchor e-book had been Abu Dhabi Funding Authority, Authorities Pension Fund World, Eastspring Investments, Amundi Funds, PineBridge World Funds and Societe Generale, HDFC Mutual Fund, ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF. It allotted 1.78 crore shares to 60 funds at ₹570 apiece.
Revealed on July 18, 2025
